AMT-191

Product

Last mentioned: Mar 3, 2026

Timeline

Invalid Date
FDA Type B Meeting

Planned follow-up meeting to define the Phase III pathway for AMT-130 in Huntington's disease.
Invalid Date
AMT-260 Data

Clinical data expected from the Phase I/IIa study in refractory mesial temporal lobe epilepsy.
Mar 2, 2026
Earnings Release

Company announces 2025 results and provides update on FDA Type A meeting.
Dec 31, 2025
Fiscal Year End

uniQure closes 2025 with $622.5M in cash and equivalents.

Stories mentioning AMT-191 1

uniQure Eyes 2029 Runway as FDA Talks for Huntington's Gene Therapy Continue

uniQure reported a robust $622.5 million cash position, extending its operational runway into late 2029. While clinical data for its Huntington’s disease candidate AMT-130 remains strong, the company is still seeking regulatory alignment with the FDA on a definitive Phase III pathway.

Mar 3, 2026 2 sources